Selectivity and Permeation in the Human Voltage-gated Proton Channel, hHv1

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): The voltage gated proton channel (hHV1) plays crucial roles in many cells in the human body. It enables rapid activity of the enzyme NADPH oxidase that produces reactive oxygen species (ROS). ROS produced by NADPH oxidase in white blood cells help kill bacteria, fungi, parasites, and other microbial invaders. However, in some situations, cells produce too much ROS, which results in a wide variety of intractable pathologies linked to inflammation damage, including neurodegenerative and fibrotic diseases (e.g., Alzheimer's disease), some cancers, atherosclerosis, hypertension, and tissue rejection. hHV1 function thus impacts numerous inflammation-associated degenerative diseases for which cures and treatments are inadequate or nonexistent. Because the innate immune response to microbial pathogens must be preserved, strategies to control ROS must not abolish ROS production completely. The proton channel is an ideal drug target, because eliminating its activity reduces but does not abolish ROS production by white cells. In addition to its effect on ROS, hHV1 has other functions in basophils, nasal mucosa, sperm, and B cells that implicate it in male fertility, allergic responses, and such diseases as cystic fibrosis, asthma, and lupus. Thus, interventions that modulate hHV1 could act as antihistamines, provide treatments of asthma, and serve as male contraceptives. A recent report indicates high hHV1 expression in metastatic breast cancer tissues, and showed that metastatic invasion was reduced by lowering hHV1 levels. This finding suggests the possibility of stopping breast cancer by hHV1 inhibition. This project will determine the key to how the proton channel does its job, which is moving protons across cell membranes, while excluding all other ions. We recently discovered the location of the "selectivity filter" of the proton channel, but the mechanism of its fundamental characteristic, extreme proton selectivity, remains enigmatic. The molecular details of this mechanism, which we will investigate in the proposed work, will provide the essential information needed to design therapies directed against hHV1 function. We will change specific parts of the protein and investigate the effects of the changes experimentally. We will also use computer modeling to predict and explain the proton selectivity mechanism. In collaboration with Drs. Nadim Hallab and Joshua Jacobs (Rush University Medical Center), we will use artificial joint rejection as a pathophysiological model of hHV1 function. We will alter hHV1 function in ways that future drugs might, and we will evaluate effects on both individual cells and the physiological system.